Companies /Healthcare
Guardant Health Inc
NASDAQ: GH Diagnostics & Research
$145.83
▲ $0.24 (+0.16%) today
Markets closed · 11:41pm ET

Guardant Health (GH) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
GH vs Market · 30-day return after each reportGHS&P 500
0%+30%+60%+62.3%+1.3%Q2 25+12.4%+0.3%Q3 25−18.9%−5.3%Q4 25+36.6%−1.7%Q1 26+1.5%+2.0%Q2 26
0%+30%+60%Q2 25Q3 25Q4 25Q1 26Q2 26
GH EPS Trend · estimate vs actualEstimateActual
$-0.40$-0.20$-0.51$-0.44Q2 25$-0.49$-0.39Q3 25$-0.47$-0.50Q4 25$-0.47$-0.45Q1 26$-0.39$-0.42Q2 26$-0.31$-0.29Q3 26
$-0.40$-0.20Q2 25Q4 25Q2 26
GH Revenue Trend · estimate vs actualEstimateActual
$0$100.0M$200.0M$300.0M$211.3M$232.1MQ2 25$237.1M$265.2MQ3 25$272.3M$281.3MQ4 25$279.1M$301.7MQ1 26$314.4M$335.0MQ2 26$350.6M$361.0MQ3 26
$0$100.0M$200.0M$300.0MQ2 25Q4 25Q2 26

How Often Does Guardant Health Beat Earnings Estimates?

Guardant Health beat EPS estimates in 4 of its last 6 reported quarters.

GH quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 GAAP net loss includes $66.3 million of stock-based compensation and related payroll tax expense and $19.0 million of 'Other' items (e.g., contingent consideration and non-recurring legal expenses), both excluded from non-GAAP net loss; GAAP net loss per share was $0.93 $-0.29 est. $-0.31 +7.76% $361.0M est. $350.6M +2.95%
Q2 2026 $-0.42 est. $-0.39 −7.80% $335.0M est. $314.4M +6.53%
Q1 2026 $-0.45 est. $-0.47 +4.98% $301.7M est. $279.1M +8.10%
Q4 2025 $-0.50 est. $-0.47 −6.52% $281.3M est. $272.3M +3.30%
Q3 2025 $-0.39 est. $-0.49 +20.33% $265.2M est. $237.1M +11.87%
Q2 2025 $-0.44 est. $-0.51 +14.53% $232.1M est. $211.3M +9.85%

Figures from SEC filings and company reports. Not investment advice.